Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
Simon Keen
Advertisement
Simon Keen, vice president Cell Line Development, Abzena
Articles by Simon Keen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Analytics, Automation, and Quality Driving the Next Era of Drug Development
2
Trends in Formulation eBook October 2025
3
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
4
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
5
